VIEW
IN BROWSER
EDITOR'S
NOTE: Big4Bio newsletters will not be
published Nov 23rd-27th; they will resume
distribution on Monday, Nov 30th.
|
|
| November
17, 2026 |
| Regional
intelligence on Drugs, Diagnostics,
Devices & Digital Health |
|
|
|
* may need subscription to view |
|
BIG4BIO
CEO WEEKLY Q&A:
Oren Gilad, Ph.D., President &
CEO, Aprea Therapeutics |
| In
this Q&A, Gilad discusses what
differentiates APR-1051 from earlier WEE1
inhibitors, the biomarker strategy behind
Aprea's approach to precision oncology,
milestones the company is working toward,
and realities of leading a clinical-stage
biotech through scientific and financial
uncertainty. More |
|
|
- Alloy Therapeutics: Introduces TEMPER, a
Proprietary siRNA Platform Designed to Advance
Targeted Extrahepatic Delivery More
- Asimov and Emergent Biosolutions: Cell Line
Development Partnership to Advance Novel
Antibodies Against Ebola More
- Biogen and Eisai: New Five-Year Lecanemab
Data From Clarity AD Study Long-Term Extension
Presented at CTAD 2026 More
- Biointron Biological: RushDATA Delivers
Wet-Lab Validation for AI-Designed Antibodies
From Molence Bio’s Mol-1
More
- Cancer Research UK and Dewpoint
Therapeutics: Partner to Advance Potential
First-in-Class Myc Condensate Modulator Into
Clinical Development More
- CervoMed: Presents Interim Data at CTAD 2026
Showing Neflamapimod Reduces Neurodegeneration
Biomarker in Nonfluent Variant Primary
Progressive Aphasia More
- Channel Medsystems: Brings Women New,
Minimally Invasive Alternative Treatment With
AcuityAI More
- Cognito: Non-Invasive, At-Home Therapy,
Spectris, Showed Consistent Slowing of
Cognitive and Functional Decline in Early
Symptomatic Alzheimer’s Disease in HOPE
Pivotal Study More
- Corsera Health: Initiates Phase 1 Trial of
COR-1004 and COR-2003, a Novel Dual-Targeting
RNAi Medicine to Prevent Cardiovascular
Disease More
- Ensem Therapeutics: Dosing of First Patients
in Phase 1/2 Clinical Trial of ETX-929, a
Potential Best-in-Class Oral Pan-KRAS
Inhibitor More
- Foundation Medicine: U.S. Food and Drug
Administration Approves FoundationOne Liquid
CDx as the First Companion Diagnostic in the
U.S. for WILSERDLY (giredestrant) in
Combination With Everolimus for ER-Positive,
HER2-Negative, ESR1-Mutated Advanced Breast
Cancer
More
- Genetix: Unveils Its Rapid Turnaround Into a
Profitable, High-Growth Commercial Leader in
Genetic Medicine for Rare Disease More
- Instem: Unveils Unified, AI-Enabled Platform
to Transform Preclinical R&D More
- Nuclera and University of Cambridge:
Researchers Demonstrate Rapid Structural
Analysis of Challenging Drug Target
More
- ProMIS Neurosciences: Licenses
Next-Generation TXP1 Brain-Selective Shuttling
Technology From Ossianix to Expand PMN310
Franchise and Pipeline More
- Quanterix: Expands Access to Blood-Based
Alzheimer's Testing in New Jersey and
Surrounding Area Through Exclusive Partnership
with Sherman Abrams Laboratory More
- Zenas
BioPharma: Launches The Distance Between
Platform to Bring Greater Visibility to the
Hidden Burden of IgG4-Related Disease More
|
|
|
CRCFO
Advisory
Reassessing your business plan?
We provide financial leadership.
Smart. Nimble. Flexible. |
|
Learn More
→ |
|
|
- Biogen Inks $411M Neurodegeneration Pact
With Protein Degrader Biotech TrimTech More
More*
More
- Calytrix Bio: Enters an Agreement to Be
Acquired by Lilly to Advance Outcomes for
Patients Living With Essential
Thrombocythemia and Myelofibrosis More
More
More More*
- Cue Biopharma: Third Quarter 2026 Financial
Results and Recent Business Highlights More
- Enanta Pharmaceuticals: Financial Results
for its Fiscal Fourth Quarter and Year-Ended
September 30, 2026
More
- Kernal Bio: Strategic Investment From
IFLI and Leadership Appointments More
- Keros Therapeutics: Additional $5 Million
Share Repurchase Authorization More
- Marrow Therapeutics: Launches With $173
Million to Develop Genetic Medicines for
Bone Marrow Disorders More
More More
More*
- Precision Optics: First Quarter Fiscal 2027
Financial Results More
- Pulmatrix: Third Quarter 2026 Financial
Results and Progress on Merger More
- Rapid Micro Biosystems: Signs Definitive
Agreement to be Acquired by Merck KGaA,
Darmstadt, Germany More
- Rapid Micro Biosystems: Third Quarter 2026
Financial Results More
- Stipple Bio: Multi-Target Multi-Modality
Oncology Research Collaboration With Lilly
More
More
More*
- Vyome: Sharp Reduction in Q3 2026 Loss Per
Share; Advances Lead VT-1953 Program
More
|
|
|
Pace®
Life Sciences
The CDMO That Takes You Further.
Your partner for Product
Development, Manufacturing,
Analytical Testing, Regulatory
Consulting & Operational
Support. |
|
Learn More
→ |
|
|
- Big4Bio CEO Weekly Q&A: Oren
Gilad, Ph.D., President & CEO, Aprea
Therapeutics More
- Biotech & Pharma Updates | November 16,
2026 More
- Preparing for Commercial Launch In Oncology
With Candel Therapeutics' Paul Peter Tak,
M.D., Ph.D. Podcast
- Subscribe to LifeSci Startup for
Updates on US Startups More
|
|
 |
|
| Slone
Partners Places Farhad Ghavami as
Chief Executive Officer at
SeqCenter |
|
Learn More
→ |
|
|
- Harbour BioMed: Appoints Dr. Sanjay Keswani
as Scientific Advisor in Neuroscience
More
- ICYMI: Bruker Institute Director, Biopharma
Entrepreneur and Immunology Leader Dr. Eicke
Latz Will Join Its Board of Directors More
- ICYMI: Gubra CEO Gets the Quick Hook; Ex-HHS
Official Brett Giroir Takes Over at Cancer
Biotech More*
- OPPORTUNITY: Director of Compliance, Remote
More
- OPPORTUNITY: Head of Market
Development & Strategy, California More
- OPPORTUNITY: Senior Vice President,
Regulatory Affairs & Quality Assurance,
Boston More
- Slone Partners: Doing More With Less
- Building the Right Nonprofit Leadership
Team in a Resource-Constrained Environment More
- Slone Partners: Leading Through AI - The New
Playbook for Healthtech Executives More
|
|
 |
|
DISCOVER COMPANIES |
|
Big4Bio: Boston Life Science
Company Directory |
|
Locate a specific company or
explore new companies in life
science. |
|
Explore
our Company Directory
|
Provided courtesy
of
|
|
|
|
|
|
|
|
You are
receiving this email because
you signed up for one of our
newsletters at Big4Bio.com,
signed up at one of our
partner or sponsor events,
or given as a gift
subscription by your firm or
organization. Unsubscribe
Big4Bio:Boston,
all rights reserved 2026
© 2026
Big4Bio, a division of
BigBio Communications. All
rights reserved.
|
|
|
|
|